Medicine
from24/7 Wall St.
23 hours agoViking Therapeutics Could Be Pharma's Next Big Buyout Target
Viking Therapeutics advances GLP-1/GIP VK2735 to Phase 3 and shows strong NASH results, positioning it as a potential acquisition target amid intense Big Pharma competition.